Acurx Pharmaceuticals

ACXP

Market cap $6.66M

ACXP Hedge Fund Activity: Q1 2026 in Review

21 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Acurx Pharmaceuticals (ACXP) for Q1 2026, worth a combined $674K — up 95% from $345K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new ACXP positions and 3 closed out — a net gain of 4 holders — while 3 added to existing stakes and 4 trimmed.

The largest buyer was Jane Street, adding an estimated $125K. The largest seller was Millennium Management, exiting entirely with an estimated $103K sold.

• 21 institutional investors held Acurx Pharmaceuticals (ACXP) as of Q1 2026, up from 18 in Q4 2025.
• Funds reported $674K of Acurx Pharmaceuticals stock for Q1 2026, up 95% quarter-over-quarter.
• 7 funds opened new Acurx Pharmaceuticals positions in Q1 2026 and 3 closed out, a net change of +4 holders.
• The largest Acurx Pharmaceuticals buyer in Q1 2026 was Jane Street, an estimated $125K added.
• The largest Acurx Pharmaceuticals seller in Q1 2026 was Millennium Management, an estimated $103K sold.

Based on aggregated 13F filings for Q1 2026.